On November 15, 2023, INVIMA, Colombia's regulatory agency, approved the BIPASS-AKI-2 early feasibility study by 3ive Labs, LLC (aka “Roivios™), with its JuxtaFlow ® (RAD) renal assist device at two research centers, one in Barranquilla, and the other one in Bucaramanga. This early feasibility study aims to recruit up to 40 subjects in Colombia and will last approximately 30 months.
We and selected third parties collect personal information and use cookies or similar technologies for technical purposes and, with your consent, for functionality, experience, measurement and “marketing (personalized ads)”.
With respect to advertising, we and 906 selected , may use precise geolocation data, and identification through device scanning in order to store and/or access information on a device and process personal data like your usage data for the following : personalised advertising and content, advertising and content measurement, audience research and services development.
You can freely give, deny, or withdraw your consent at any time by accessing the preferences panel. If you give consent, it will be valid only in this domain. Denying consent may make related features unavailable.
Use the “Accept” button to consent. Use the “Reject” button or close this notice to continue without accepting.
